

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients

OPEN ACCESS

Edited by:

Jun Zhang, University of Kansas Medical Center, United States

Reviewed by:

Lei Xian, Second Affiliated Hospital of Guangxi Medical University, China Patricia Iranzo, Vall d'Hebron Institute of Oncology, Spain Mingming Wu, Harbin Medical University, China Yan Chen, Sichuan Cancer Hospital, China

*Correspondence:

Yefei Zhang zhangyefei88@126.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology

Received: 25 February 2022 Accepted: 13 June 2022 Published: 10 August 2022

Citation:

Yang W, Xuan B, Chen M, Li X, He J, Si H and Zhang Y (2022) Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. Front. Oncol. 12:883514. doi: 10.3389/fonc.2022.883514 Wenchao Yang^{1†}, Bixia Xuan^{1†}, Mengqi Chen¹, Xiaofang Li¹, Jiana He¹, Haiyan Si² and Yefei Zhang^{3*}

¹ Department of Pharmacy, Traditional Chinese Medical Hospital of Zhuji, Zhuji, China, ² Department of Gastroenterology, Traditional Chinese Medical Hospital of Zhuji, Zhuji, China, ³ Department of Pharmacy, Zhuji People's Hospital of Zhejiang Province, Zhuji, China

Objective: Meta analysis was used to compare the efficacy and safety of immune checkpoint inhibitor and docetaxel in the treatment of non-small cell lung cancer.

Methods: CNKI, CBM, PubMed, EMBASE, Cochrane Library, web of science and other databases were searched by computer, and the randomized controlled trials of immune checkpoint inhibitors and docetaxel in the treatment of NSCLC published as of February 2022 were collected. Two researchers searched independently, screened the literature and extracted the data according to the nanodischarge criteria, and used Revman5.4. The included studies were statistically analyzed, and publication bias was analyzed with Egger test in Stata12.

Results: A total of 8 RCTs were included, including 2444 cases treated with immune checkpoint inhibitors and 2097 cases treated with docetaxel. Compared with docetaxel, the overall survival (HR = 1.40, 95%CI: 1.30-1.50, P < 0.00001) and progression free survival (HR = 1.22, 95%CI: 1.13-1.32, P < 0.00001) of NSCLC treated with ICIs were longer. The risk ratio of any grade of adverse reactions (HR = 0.41, 95%CI: 0.32-0.52, P < 0.00001) and above grade III adverse reactions (HR = 0.27, 95%CI: 0.18-0.41, P < 0.00001) in the treatment of NSCLC with ICIs was lower. There was no publication bias in Egger test.

Conclusion: Compared with docetaxel, immune checkpoint inhibitor treatment can improve the clinical efficacy of NSCLC patients and has a lower incidence of adverse reactions. This treatment may be a promising treatment for NSCLC patients.

Keywords: immune checkpoint inhibitors, docetaxel, non small cell lung cancer, overall survival, progression free survival, security

1

INTRODUCTION

Lung cancer is one of the most common malignant tumors in China. Its incidence rate and mortality rate are the first in all tumors. Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which NSCLC accounts for 85%. Non-small cell lung cancer includes squamous cell carcinoma, adenocarcinoma and large cell carcinoma. The etiology of lung cancer is complex. At present, it is considered that it is mainly related to smoking, air pollution, occupational factors and changes in molecular genetics. The early symptoms of lung cancer are not obvious. Later, there are often symptoms such as cough, blood in sputum, chest pain and so on (1, 2). Due to the limited diagnostic tools currently used, 75% of patients were found to be in advanced stage. The prognosis of most patients is poor. Based on the stage of the disease at the time of diagnosis, the 5-year survival rate of patients is 4% - 17% (3). At present, docetaxel chemotherapy is one of the most commonly used second-line treatments for NSCLC (2, 3). Its mechanism is to increase the polymerization of tubulin, and then inhibit the depolymerization of microtubules, and thus inhibit the division and growth of tumor cells (4). However, docetaxel has poor efficacy and high toxicity in the treatment of NSCLC. Therefore, it is necessary to explore new treatment methods to prolong the survival time and improve the quality of life of patients.

In recent years, with the rapid development of tumor immunology, immunotherapy has become another new tumor treatment method besides surgery, chemotherapy and radiotherapy. Great breakthroughs have been made in the research of immune checkpoint inhibitors, and the role of inhibitory antibodies in clinical treatment trials of malignant tumors has also been recognized. PD-1 is a cell surface receptor, which is highly expressed on activated T cells and is considered to be a marker of T cell failure. It can regulate the activity of T cells, activate the apoptosis of tumor specific T cells and inhibit the apoptosis of regulatory T cells, so as to inhibit immune response and promote self tolerance (5). PD-L1 is expressed on some types of tumor cells and antigen-presenting cells and is considered to be a co suppressor of immune response. It can be bind to PD-1, activate PD-1/PD-L1 pathway, inhibit downstream signal transduction and T cell biological function, lead to tumor specific T cell failure and apoptosis, and make tumor cells escape immune surveillance (6). PD-1/PD-L1 pathway induces and maintains immune tolerance in tumor microenvironment and promotes tumor development. In this study, randomized controlled trials (RCTs) of ICIs and docetaxel monotherapy in the treatment of NSCLC were searched and efficacy and safety were evaluated by meta-analysis. The results obtained can provide a reference for clinical treatment.

METHODS AND MATERIALS

Search Strategy

We used computers to search PubMed, EMBASE, Cochrane Library, Web of science database, etc. Chinese search terms: immune checkpoint inhibitor, docetaxel, non-small cell lung cancer, randomized controlled trial; English search terms: ICIs, docetaxel, non small cell lung cancer, NSCLC, randomized controlled trials, RCTs. The search deadline is February 2022.

Study Selection

Inclusion criteria: ① Literature: retrospective study, prospective study; ② The subjects were patients with NSCLC diagnosed by clinicopathological examination; ③ Intervention measures: patients in the experimental group treated with ICI monotherapy and patients in the control group treated with docetaxel monotherapy; ④ The primary clinical outcome measures were overall survival (OS) and progression free survival (PFS). The secondary outcome measures were adverse reactions at any level and adverse reactions above grade 3.

Exclusion criteria: ① repeatedly published literature; ② Documents that cannot obtain original data or contact the author to obtain the original text; ③ Abstract, review, meta-analysis, case report and animal experiment; ④ Non Chinese and English literature.

Literature Screening and Data Extraction

Two researchers independently read the initial literature titles and abstracts according to the inclusion and exclusion criteria, screened the literature that may meet the inclusion criteria by reading the full text, and extracted the data according to the predesigned table, including the first author, year of publication, number of patients, OS, PFS and adverse reactions. In case of differences, the two researchers shall discuss and solve them.

Bias Risk Assessment

We assessed the quality of inclusion in clinical randomized controlled trials, met the criteria proposed in the Cochrane manual for systematic evaluation of interventions (5.1.0), and evaluated the generation of random sequences, allocation concealment, blinding of participants, blinding of outcome evaluation, and incomplete outcome data to ensure a low incidence of bias.

Statistical Analysis

We use Revman5.4 software to analyze the data of the included studies. Relative risk ratios (RR) and 95% confidence interval (95%CI) were used as effect indexes for counting data, and the difference was statistically significant (P < 0.05). I² is used to evaluate the heterogeneity. If the heterogeneity test result I² is less than 50%, it means that there is no statistical heterogeneity among the research results, and the fixed effect model is used; If the heterogeneity test result I² > 50%, analyze the source of heterogeneity. If the heterogeneity still exists, select the random effect model to estimate the combined effect.

RESULTS

Literature Search and Screening

205 literatures (including 86 PubMed, 72 Cochrane, 22 Embase, 20 CNKI, and Wanfang VIP5) were searched by computer, and

55 were selected according to the title and abstract. After full-text analysis and evaluation, 47 literatures with abnormal data, incomplete information or unavailable due to non comparative research were excluded, and finally 8 (7–14) literatures were included for systematic evaluation and meta-analysis. The process of literature screening is shown in **Figure 1**. Among them, 2444 patients were treated with ICIs monotherapy and 2097 patients were treated with docetaxel monotherapy. **Table 1** summarizes the basic characteristics and main evaluation indicators of the included research.

Quality Assessment Results

The quality assessment results are shown in **Figures 2A, B**. All included studies had a low risk of bias.

Meta Analysis Results of Effectiveness of ICIs and Docetaxel

OS comparison 8 RCTs reported the OS of patients, and there were no statistically significant differences between studies. The results of meta-analysis showed that the OS of ICIS treatment group was longer than that of docetaxel chemotherapy group, and the difference was statistically significant (HR = 1.40, 95% CI: 1.30-1.50, P < 0.00001), indicating that the efficacy of ICIs in the treatment of NSCLC was better than that of docetaxel chemotherapy (as shown in **Figure 3**).

PFS comparison Five RCTs reported PFS of patients, and there were no statistically significant differences between studies. The results of meta-analysis showed that the PFS of ICIS treatment group was longer than that of docetaxel chemotherapy group, and the difference was statistically significant (HR = 1.22, 95%CI: 1.13-1.32, P < 0.00001), indicating that the efficacy of ICIs in the treatment of NSCLC was better than that of docetaxel chemotherapy (as shown in **Figure 4**).

Results of Safety Meta-Analysis of ICIs and Docetaxel

Adverse reactions at any level Five RCTs reported typical adverse reactions at any level (including fatigue, nausea, ashenia, diarrhea and anemia). There were no statistically significant differences between studies. The results of meta-analysis showed that the risk of adverse reactions at any level in the ICIs treatment group was lower than that in the docetaxel chemotherapy group, and the difference was statistically significant (HR = 0.41, 95%CI: 0.32-0.52, P < 0.00001), indicating that the safety of ICIs is superior to docetaxel monotherapy in NSCLC (as shown in **Figure 5**).

Adverse reactions above grade III Five RCTs reported typical adverse reactions above grade III (including fatigue, nausea, ashenia, diarrhea and anemia), and there were no statistically significant differences between studies. The results of meta-analysis showed that the risk of grade III and above adverse reactions in the ICIs treatment group was lower than that in the docetaxel chemotherapy group, and the difference was statistically significant (HR = 0.27, 95%CI: 0.18-0.41, P < 0.00001), indicating that the safety of ICIs is superior to docetaxel monotherapy in NSCLC(as shown in **Figure 6**).

Sensitivity Analysis and Publication Bias Assessment

Publication bias assessment was performed only in OS and PFS. Egger test in Stata12 software was used for publication bias test. In a total of 8 studies with OS and PFS as outcome indicators, the results of publication bias test indicated that there was no publication bias OS(P = 0.051) and PFS(P = 0.255), as shown in **Figure 7**.





TABLE 1	Basic characteristics of included studies and main evaluation indicators (7–14).
---------	--

First Author	Year	Clinical trial number	Phase	Type of Cancer	NO. of Patients with ICI	NO. of Patients with Docetaxel	HR for OS [95% CI]	p-Value for OS	HR for PFS [95% CI]	p-Value for PFS
Leora Horn (8)	2017	NCT01673867	III	NSCLC	427	427	0.72 [0.62,0.84]	0.001	NA	NA
H. Borghaei (9)	2015	NCT01673867	Ш	NSCLC	292	290	0.73 [0.59,0.89]	0.002	0.92 [0.77,1.11]	0.39
Julie Brahmer (10)	2015	NCT01642004	Ш	NSCLC	135	137	0.59 [0.44,0.79]	0.001	0.62 [0.47,0.81]	0.001
Shun Lu (11)	2021	NCT02613507	Ш	NSCLC	338	166	0.75 [0.61,0.93]	0.001	0.79 [0.65,0.98]	0.001
Yi-Long Wu (12)	2019	NCT02613507	Ш	NSCLC	338	166	0.68	0.0006	0.77	0.0147
Roy S Herbst (13)	2015	NCT01905657	Ш	NSCLC	345	343	0.71 [0.58,0.88]	0.0008	0.88 [0.74,1.05]	0.07
Louis Fehrenbacher (14)	2016	NCT01903993	II	NSCLC	144	143	0.73 [0.53,0.99]	0.04	NA	NA
Achim Rittmeyer (15)	2016	NCT02008227	III	NSCLC	425	425	0.73 [0.62,0.87]	0.0003	NA	NA

ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; HR, Hazard ratio; NA, Not available; PFS, Progression free survival; OS, Overall survival.

DISCUSSION

In recent years, the choice of standard treatment for NSCLC patients has gradually changed from routine first-line drugs to immune checkpoint inhibitor (ICIs) therapy, or as a monotherapy, or combined with chemotherapy, anti angiogenic antibodies or other forms of ICIs. ICIs, an



antibody against PD-1 or PD-L1, was approved for secondline and third-line treatment in patients with metastatic NSCLC without treatable driver mutations in 2015 (15). Since then, ICIs has been approved for first-line treatment, or for tumors with PD-L1 expression \geq 50% alone, or in combination with chemotherapy independent of receptor status (16). Some patients treated with ICIs have particularly long-lasting response and survival. The study confirmed that up to 16% of patients with stage IV non-small cell lung cancer received second-line treatment with PD-1 inhibitor nivolumab and 31.9% received first-line treatment with PD-1 inhibitor pembrolizumab, with a survival time of 5 years (17). Another study showed that 4-year OS rates in POPLAR were 14.8% and 8.1% (and those in OAK were 15.5% and 8.7% for atezolizumab and docetaxel, respectively. However, it is worth noting that some patients with low PD-L1 expression may have poor efficacy in the treatment of tumors with immune checkpoint inhibitors. Therefore, it is very important to select biomarkers that can effectively predict the efficacy of PD-1/PD-L1 inhibitors, which is also an urgent problem to be solved in immunotherapy at this stage (18). At the same time, immune checkpoint inhibitors may cause immune related adverse reactions and infusion related reactions in the process of clinical application, which still needs further research (19).

In this meta-analysis, we evaluated the efficacy of ICIs drugs and docetaxel in patients with NSCLC, and selected OS and PFS as the primary outcomes. The results showed that ICIs improved the HR and p of OS and PFS in terms of effectiveness, indicating that patients receiving immunotherapy had better OS and PFS than patients receiving docetaxel. In terms of safety, the risk ratio of adverse reactions at any level and above in the ICIs treatment group was significantly lower than that in the docetaxel group, suggesting that the safety of ICIs treatment was higher than that of docetaxel, and it is not easy to produce common and typical adverse reactions (fatigue, nauesa, ashenia, diarrhea, anemia).






FIGURE 3 | Meta-analysis results of OS between ICIs group and docetaxel group.



Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl 2.2.1 Fatigue	
	M-H, Random, 95% Cl
H. Borghaei 2015 46 292 78 290 6.5% 0.59 [0.42, 0.81]	-
Julie Prammer 2015 21 135 42 137 5.7% 0.51 [0.32, 0.81]	
Roy S Herbst 2015 46 345 49 343 6.2% 0.93 [0.64.1.36]	
Shun Lu 2021 35 338 39 166 6.0% 0.44 [0.29, 0.67]	-
Yi-Long Wu 2019 33 338 39 166 5.9% 0.42 [0.27, 0.64]	—
Subtotal (95% Cl) 1448 1102 30.3% 0.56 [0.42, 0.75] Total events 181 247	•
Total events 181 247 Heterogeneity: Tau ² = 0.07; Chi ² = 10.56, df = 4 (P = 0.03); I ² = 62%	
Test for overall effect: $Z = 3.95$ (P < 0.0001)	
2.2.2 Nausea	19274
H. Borghaei 2015 34 292 70 290 6.2% 0.48 [0.33, 0.70]	1
Julie Brahmer 2015 12 135 30 137 4.8% 0.41 [0.22, 0.76] Roy S Herbst 2015 37 345 45 343 6.0% 0.82 [0.54, 1.23]	
K0/SHERDS12015 37 345 45 343 6.0% 0.82(0.54,1.23) Subtota(95% CI) 772 770 17.1% 0.55[0.37,0.35]	•
Total events 83 145	
Heterogeneity: Tau ⁺ = 0.08; Chi ² = 4.88, df = 2 (P = 0.09); P = 59% Testfor overall effect: Z = 2.75 (P = 0.006)	
2.2.3 Asthenia	
H. Borghaei 2015 29 292 47 290 5.9% 0.61 [0.40, 0.95]	
Julie Brahmer 2015 13 135 18 137 4.6% 0.73 [0.37,1.44] Rov S Herbst 2015 20 345 35 343 5.4% 0.57 [0.33 0.96]	
Roy S Herbst 2015 20 345 35 343 5.4% 0.57 [0.33, 0.96] Subtotal (95% Cl) 772 770 15.9% 0.62 [0.46, 0.84]	•
Total events 62 100	
Heterogeneity: Tau [#] = 0.00; Chi [#] = 0.35, df = 2 (P = 0.84); i [#] = 0% Test for overall effect: Z = 3.13 (P = 0.002)	
2.2.4 Diarrhea	
H. Borghaei 2015 22 292 62 290 5.8% 0.35 [0.22, 0.56]	
Julie Brahmer 2015 10 135 26 137 4.5% 0.39 [0.20, 0.78]	
Roy S Herbst 2015 24 345 56 343 5.8% 0.43 [0.27, 0.67]	
Subtotal (95% Cl) 772 770 16.1% 0.39 [0.29, 0.52]	•
Total events 56 144	
Heterogeneity, $Tau^{\mu} = 0.00$; $Ch^{\mu} = 0.33$, $dt = 2$ ($P = 0.85$); $P = 0\%$. Test for overall effect $Z = 6.34$ ($P < 0.00001$)	
2.2.5 Anemia	
H. Borghaei 2015 6 292 53 290 3.9% 0.11 [0.05, 0.26]	
Julie Brahmer 2015 2 135 28 137 2.0% 0.07 [0.02, 0.30]	
Roy S Herbst 2015 10 345 40 343 4.6% 0.25 [0.13, 0.49] Shun Lu 2021 14 338 41 166 5.1% 0.17 [0.09, 0.30]	
ViL.long Wu 2019 14 338 41 166 5.1% 0.17 [0.09, 0.30]	<u> </u>
Subtotal (95% CI) 1448 1102 20.7% 0.17 [0.12, 0.23]	•
Total events 46 203	
Heterogeneity: Tau [#] = 0.00; Chi [#] = 3.63, df = 4 (P = 0.46); i [#] = 0% Test for overall effect: Z = 11.23 (P < 0.00001)	
Total (95% Cl) 5212 4514 100.0% 0.41 [0.32, 0.52]	•
Total events 428 839	· ·
Heterogeneity: Tau ² = 0.20; Chi ² = 75.17, df = 18 (P < 0.00001); I ² = 76%	0.1 1 10
Test for overall effect: Z = 7.38 (P < 0.00001) Test for subdroup differences: Chi² = 46.13. df = 4 (P < 0.00001), I² = 91.3%	s [Docetaxel] Favours [ICIs]
restron suburbub dimerences. On = 40.15. un = 414 > 0.000011. F= 31.3 %	

Study or Subgroup	ICIS Events Total	Docetaxel Events Tot	al Weight	Risk Ratio	Risk Ratio M-H, Fixed, 95% Cl
2.1.1 Fatigue	Liono Iota	Literite 160	a recigin	in the thread bolt of	in the two of two of the two of two o
H. Borghaei 2015	3 292	13 29	0 13.0%	0.23 [0.07, 0.80]	
Julie Brahmer 2015	1 135			0.10 [0.01, 0.78]	
Roy S Herbst 2015	3 345			0.99 [0.20, 4.89]	
Shun Lu 2021	3 338			0.29 [0.07, 1.22]	
Yi-Long Wu 2019	3 338			0.29 [0.07, 1.22]	
Subtotal (95% CI)	1448			0.28 [0.15, 0.53]	•
Total events	13	36	L OUL!	onco for rot oroof	
Heterogeneity: Chi#=					
Test for overall effect					
	10.	10			
2.1.2 Nausea					
H. Borghaei 2015	2 292			0.99 [0.14, 7.00]	
Julie Brahmer 2015	0 135			0.20 [0.01, 4.19]	5 C C C C C C C C C C C C C C C C C C C
Roy S Herbst 2015	1 345			0.99 [0.06, 15.83]	
Subtotal (95% CI)	772	77	0 5.5%	0.64 [0.17, 2.43]	
Total events	3	5			
Heterogeneity: Chi ² =	0.85, df = 2 (P =	0.65); I ² = 0%			
Test for overall effect	Z = 0.66 (P = 0.5	i1)			
2.1.3 Asthenia	10 000		0. 10.000		7.72
H. Borghaei 2015	1 292			0.17 [0.02, 1.37]	
Julie Brahmer 2015	0 135			0.09 [0.01, 1.65]	and the second se
Roy S Herbst 2015	1 345			0.17 [0.02, 1.37]	
Subtotal (95% CI)	772		0 17.4%	0.14 [0.04, 0.54]	
Total events	2	17			
Heterogeneity: Chi ² =					
Test for overall effect	. Z = 2.89 (P = 0.0	104)			
2.1.4 Diarrhea					
H. Borghaei 2015	2 292	3 29	0 3.0%	0.66 [0.11, 3.93]	
Julie Brahmer 2015	0 135			0.14 [0.01, 2.78]	
Roy S Herbst 2015	2 345			0.28 [0.06, 1.36]	
Subtotal (95% CI)	772			0.33 [0.11, 0.96]	
Total events	4	13		also for it also f	
Heterogeneity: Chi ² =	0.92 df = 2 (P =				
Test for overall effect					
2.1.5 Anemia	12 1222		6) (maka		
H. Borghaei 2015	1 292			0.14 [0.02, 1.15]	
Julie Brahmer 2015	0 135			0.11 [0.01, 2.07]	No. Contraction of the second
Roy S Herbst 2015	3 345			0.60 [0.14, 2.48]	and the second s
Shun Lu 2021	1 338			0.16 [0.02, 1.56]	
Yi-Long Wu 2019	1 338			0.16 [0.02, 1.56]	
Subtotal (95% CI)	1448		2 24.4%	0.24 [0.10, 0.56]	-
Total events	6	22			
Heterogeneity: Chi ² =					
Test for overall effect	Z = 3.26 (P = 0.0	101)			
Total (95% CI)	5212		4 100.0%	0.27 [0.18, 0.41]	•
Total events	28	93	222		r r 1 r
Heterogeneity: Chi ² =			%		0.005 0.1 1 10
Test for overall effect					Favours [Docetaxel] Favours [ICIs]
Test for subaroup dit	ferences: Chi ² =	2.69. df = 4 (P	= 0.61). ² = 1	0%	



Many international researches also show similar results, Khan M et al. (20) shows that compared with chemotherapy drugs, ICI therapy (nivolumab, pembrolizumab, atezolizumab) leads to better OS (HR 0.72 [95% CI 0.63, 0.82; P <. 00001]), PFS (HR 0.84 [95% CI 0.72), 0.97; P <. 02]) and ORR (odds ratio [OR] 1.52 [95% CI 1.08, 2.14; P <. 02]). At the same time, higher safety was observed with ICI therapy (OR 0.31 [95% CI 0.26, 0.38; P <. 00001]). The results of this study are basically consistent with those of previous international studies.

This study also has some limitations: ① after systematic retrieval and screening, only 8 literatures were included for systematic evaluation and meta-analysis, and the sample size is too small; ③ The heterogeneity of individual statistical results may affect the credibility of the research results; ③ Different types of NSCLC in different studies may increase heterogeneity and affect the reliability of the results. However, in the study, in order to better reduce the above bias, when implementing retrieval and data consolidation, this study will report scientifically and objectively as much as possible in accordance with the Cochrane system evaluation guidance manual.

In conclusion, compared with docetaxel, ICIs can prolong the OS and PFS of patients with NSCLC, with better clinical efficacy. This therapy may be a promising treatment. However, it still needs to be further confirmed by studies with multiple centers, larger sample size and higher quality.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

WY and BX searched the database and analysed the data. MC, XL, JH and HS selected the study and extracted the data. WY and

REFERENCES

- Mao Y, Yang D, He J, Krasna MJ. Epidemiology of Lung Cancer. Surg Oncol Clin N Am (2016) 25(3):439–45. doi: 10.1016/j.soc.2016.02.001
- Rivera GA, Wakelee H. Lung Cancer In Never Smokers. Adv Exp Med Biol (2016) 893:43–57. doi: 10.1007/978-3-319-24223-1_3
- Gavin S Jones DRB. Recent Advances in the Management of Lung Cancer. Clin Med (Lond) (2018) 18(Suppl 2):s41–6. doi: 10.7861/clinmedicine.18-2-s41
- Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, et al. Impact of Docetaxel Plus Ramucirumab in a Second-Line Setting After Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer: A Retrospective Study[J]. *Thorac Cancer* (2022) 13(2):173–81. doi: 10.1111/ 1759-7714.14236
- Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. *Front Cell Dev Biol* (2020) 8:672. doi: 10.3389/fcell.2020.00672
- Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C. New PDL1 Inhibitors for Non-Small Cell Lung Cancer: Focus on Pembrolizumab. Onco Targets Ther (2018) 11:4051–64. doi: 10.2147/OTT.S154606
- Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *J Clin Oncol* (2017) 35 (35):3924–33. doi: 10.1200/JCO.2017.74.3062
- Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(17):1627–39. doi: 10.1056/ NEJMoa1507643
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 373(2):123–35. doi: 10.1056/ NEJMoa1504627
- Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: 2-Year Follow-Up From a Randomized, Open-Label, Phase 3 Study (CheckMate 078). Lung Cancer (2021) 152:7–14. doi: 10.1016/j.lungcan.2020.11.013
- 11. Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. J Thorac Oncol (2019) 14(5):867–75. doi: 10.1016/j.jtho.2019.01.006
- Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. *Lancet* (2016) 387(10027):1540–50. doi: 10.1016/S0140-6736 (15)01281-7
- 13. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab Versus Docetaxel for Patients With Previously Treated

BX wrote the manuscript. YZ reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the clinical fund project of Zhejiang Medical Association in 2021 (2021ZYC-A193).

Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. *Lancet* (2016) 387(10030):1837–46. doi: 10.1016/S0140-6736(16)00587-0

- Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab Versus Docetaxel in Patients With Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. *Lancet* (2017) 389(10066):255–65. doi: 10.1016/S0140-6736(16)32517-X
- Guilleminault L, Carmier D, Heuze-Vourc'h N, Diot P, Pichon E. [Immunotherapy in Non-Small Cell Lung Cancer: Inhibition of PD1/PDL1 Pathway]. *Rev Pneumol Clin* (2015) 71(1):44–56. doi: 10.1016/ j.pneumo.2014.11.004
- Ma X, Zhang Y, Wang S, Wei H, Yu J. Immune Checkpoint Inhibitor (ICI) Combination Therapy Compared to Monotherapy in Advanced Solid Cancer: A Systematic Review. J Cancer (2021) 12(5):1318–33. doi: 10.7150/jca.49174
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol (2019) 37(7):537– 46. doi: 10.1200/JCO.18.00149
- Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol (2020) 1248:33–59. doi: 10.1007/978-981-15-3266-5_3
- Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. *Clin Cancer Res* (2019) 25(15):4592–602. doi: 10.1158/1078-0432.CCR-18-1538
- Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, et al. Comparative Analysis of Immune Checkpoint Inhibitors and Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. *Med (Baltimore)* (2018) 97(33):e11936. doi: 10.1097/ MD.000000000011936

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yang, Xuan, Chen, Li, He, Si and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.